To hear about similar clinical trials, please enter your email below
Trial Title:
A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy
NCT ID:
NCT05828875
Condition:
Assessing the Current Quality of Life Status of Esophageal Cancer Patients Who Have Undergone Radical Chemoradiotherapy/Radiotherapy and Long-term Survival
Conditions: Official terms:
Esophageal Neoplasms
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Other
Intervention name:
questionnaire investigation
Description:
Conduct a questionnaire survey on patients' quality of life, nutrition, and psychology
Summary:
This study is a multicenter cross-sectional survey of esophageal cancer patients who
underwent radical chemoradiotherapy/radiotherapy from July 2017 to July 2020 in various
medical centers, and who survived without disease progression at the time of the survey.
The purpose of this study is to evaluate the current quality of life, as well as the
incidence of long-term toxic side effects, nutritional status, and psychological status
of esophageal cancer patients cured by radiotherapy.
Criteria for eligibility:
Study pop:
The age at the time of radiotherapy is between 18-75 years old, and the age at the time
of investigation is<80 years old;
- Histologically confirmed esophageal squamous cell carcinoma without undergoing
surgical resection;
- Received radical chemoradiotherapy/radiotherapy from July 2017 to July 2020,
currently alive and without disease progression;
- Radiotherapy dose ≥ 45Gy.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Voluntarily accept this survey and research;
- The age at the time of radiotherapy is between 18-75 years old, and the age at the
time of investigation is<80 years old;
- Histologically confirmed esophageal squamous cell carcinoma without undergoing
surgical resection;
- Received radical chemoradiotherapy/radiotherapy from July 2017 to July 2020,
currently alive and without disease progression;
- Radiotherapy dose ≥ 45Gy.
Exclusion Criteria:
- Patients who do not cooperate with this survey;
- Patients who have died at the time of investigation;
- Patients who experience tumor progression within the time frame from the end of
radiotherapy to receiving this survey;
- Patients diagnosed with other malignant tumors within the time frame from the end of
radiotherapy to receiving this survey;
- Patients with incorrect contact information and missing visits
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Tianjin Medical University Cancer Institute & Hospital
Address:
City:
Tianjin
Zip:
300000
Country:
China
Contact:
Last name:
Qingsong Pang, PHD
Phone:
+86-22-23340123-1121
Start date:
August 1, 2023
Completion date:
July 1, 2024
Lead sponsor:
Agency:
Tianjin Medical University Cancer Institute and Hospital
Agency class:
Other
Source:
Tianjin Medical University Cancer Institute and Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05828875
